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ABSTRACT: Although chemotherapy is designed to eradicate tumor cells, it also has significant effects on normal
tissues. The platinum-induced fatty acid 16:4(n-3) (hexadeca-4,7,10,13-tetraenoic acid) induces systemic resistance
to a broad range ofDNA-damaging chemotherapeutics.We show that 16:4(n-3) exerts its effect by activating splenic
F4/80+/CD11blow macrophages, which results in production of chemoprotective lysophosphatidylcholines (LPCs).
Pharmacologic studies, together with analysis of expression patterns, identified GPR120 on F4/80+/CD11blow
macrophages as the relevant receptor for 16:4(n-3). Studies that used splenocytes fromGPR120-deficient mice have
confirmed this conclusion. Activation of the 16:4(n-3)-GPR120 axis led to enhanced cPLA2 activity in these splenic
macrophages and secretion of the resistance-inducing lipidmediator, lysophosphatidylcholine(24:1). These studies
identify anovel andunexpected function forGPR120and suggest that antagonistsof this receptormightbeeffective
agents to limit development of chemotherapy resistance.—Houthuijzen, J. M., Oosterom, I., Hudson, B. D.,
Hirasawa, A., Daenen, L. G. M., McLean, C. M., Hansen, S. V. F., van Jaarsveld, M. T. M., Peeper, D. S., Jafari
Sadatmand, S., Roodhart, J.M. L., van de Lest, C. H. A., Ulven, T., Ishihara, K.,Milligan, G., Voest, E. E. Fatty acid
16:4(n-3) stimulates a GPR120-induced signaling cascade in splenic macrophages to promote chemotherapy
resistance. FASEB J. 31, 2195–2209 (2017). www.fasebj.org
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Since their deorphanization as GPCRs that respond to
a diverse range of both saturated and unsaturated
long-chain fatty acids, there has been growing interest
in both GPR40 (systematically named free fatty acid
receptor 1) and GPR120 (free fatty acid receptor 4)
(1, 2). Both receptors are expressed by a number of
endocrine cells, including cells of the pancreas and
entero-endocrine cells of the gut (3–5). Here, free fatty
acid–induced release of insulin, incretins, and satiety-
regulating hormones have focused attention on the
potential of synthetic agonists of one or both of these
receptors to provide novel approaches to regulate
glycaemia and to treat metabolic disorders, such as
type II diabetes (4, 6–8); however, as with most other
GPCRs, both GPR40 and GPR120 are thought to be
expressed more broadly. This includes immune cell
subsets (9, 10), lung (11–13), andprecursors of bone and
adipocytes (9, 13–15), and there is evolving interest in
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whether this might translate into opportunities for li-
gands that target these receptors in wider therapeutic
settings.
Although both GPR40 andGPR120 can be activated by
a range of long-chain free fatty acids (4), including n-3
fatty acids that are routinely considered to be health ben-
eficial (16, 17),more attentionhasbeendirected towardn-3
fatty acids as activators of GPR120 (4, 9). Furthermore,
quantitatively minor lipids, including branched palmitic
acid esters of hydroxy stearic acids, have more recently
been suggested to produce key effects as activators of
GPR120 (18).
There has been growing evidence that fatty acid–
induced activation of GPR40 and/or GPR120 can reg-
ulate tumor growth and migration of various cancer
types, including melanoma and prostate cancers (19,
20). We have previously identified mechanisms of re-
versible and systemic chemotherapy resistance that
involve lipid-mediated crosstalk between mesenchy-
mal stem cells, splenic macrophages, and tumor cells.
Within these studies, we showed that mesenchymal stem
cells can secrete 2 distinct polyunsaturated fatty acids
{12-S-hydroxy-5,8,10-heptadecatrienoic acid (12-S-HHT)
and hexadeca-4,7,10,13-tetraenoic acid [16:4(n-3)]} upon
stimulation with platinum-containing chemothera-
peutics (Supplemental Fig. 1) (21). These platinum-
induced fatty acids (PIFAs) convey resistance to a
broad range of DNA-damaging chemotherapeutics in
various tumormousemodels (21). PIFAs do not induce
resistance directly to tumor cells but rather function
via F4/80+/CD11blow macrophages that are located in
the red pulp of the spleen (22).
Herein, we assess the contribution of free fatty acid
receptors GPR40 and GPR120 to chemoresistance in-
duced by 16:4(n-3), as we show that these GPCRs are
expressed exclusively by the F4/80+/CD11blow subpopu-
lation of splenic macrophages that are known to induce
chemoresistance. By using combinations of selective
pharmacologic activation and inhibition of GPR40 and
GPR120 in concert with splenocytes isolated from both
wild-type and GPR120-deficient mice, we show that
effects of 16:4(n-3) are induced specifically via GPR120
and that activation of this receptor results in a signaling
cascade within splenocytes that involves cytosolic
PLA2-mediated generation and release of a specific
isoform of lysophosphatidylcholine (LPC), which acts
as the ultimate inducer of chemoresistance.
MATERIALS AND METHODS
Reagents
16:4(n-3) was isolated from Ulva pertusa as previously de-
scribed (23). GW1100 was purchased from Cayman Chemical
(Ann Arbor, MI, USA). GW9508 and AACOCF3 (arachidonyl
trifluoromethyl ketone) were purchased from Tocris (Bristol,
United Kingdom). NCG21, TUG-891, AH-7614, and TUG-
1197 were synthesized as described previously (24–27). For
fluorescence-activated cell sorting (FACS) analysis, the fol-
lowing Abs were used: rat anti-mouse F4/80-FITC and rat
anti-mouse CD11b-APC (both from eBioscience, San Diego,
CA, USA). For immunohistochemical staining, the following
Abs were used: anti-gH2AX (gamma histone 2A family
member X2577; Cell Signaling Technologies, Danvers, MA,
USA), anti-GPR120 (NBP1-00858; Novus Biologicals, Lit-
tleton, CO, USA) and poly–horseradish peroxidase (HRP)
goat anti-rabbit/rat/mouse (Immunologic, Duiven, The
Netherlands). ForWestern blotting, the followingAbswere
used: rabbit anti–phospho-cPLA2 (Ser505, 2831; Cell Sig-
naling Technologies), mouse anti–b-actin (NB600-501; Novus
Biologicals), and goat anti-mouse HRP (Santa Cruz Bio-
technology, Santa Cruz, CA, USA).
Animal models
C26 cells were implanted in BALB/c and LLC cells were
implanted in C57bl/6 mice (both from Charles River Labs,
Northampton, MA, USA). For all experiments, 8- to 10-wk-
old male mice were used. At d 0, mice were subcutaneaously
injected with 1 3 106 (for C26) or 0.5 3 106 (for LLC) tumor
cells. Mice were splenectomized 1 d after tumor cell in-
jection. Spleens from the surgery were used to prepare
splenic conditioned medium (sCM). At d 8 (C26) or d 10
(LLC), when the tumors reached a size of 50–100 mm3,
animals were randomly assigned to groups and treatment was
started. Mice received an intraperitoneal injection of 6 mg/kg
cisplatin alone or in combination with an subcutaneaous in-
jection of 200ml sCMor 100ml of LPC(24:1) or LPC(24:0), both 10
nmol. Blinded tumor volume measurements were taken once
every 2 d by using a digital caliper. Tumor volume was de-
termined as length 3 width2 3 0.5. Control mice received ap-
propriate vehicles. All experimental animal procedures
conducted in Utrecht, The Netherlands, were approved by the
University Medical Center Animal Ethics Committee and
were in agreement with the current Dutch laws on animal
experiments. All experimental animal procedures conducted
in Kyoto, Japan, were approved by the Kyoto University
Animal Care and Use Committee. To show a difference of 20%
in tumor volume with an SD of 10% and a type I error (a) of 5%
using a power of 90%, a minimum of 8 mice per treatment
group were required.
Cell lines
C26 andLLC cells (both fromAmericanTypeCultureCollection,
Manassas, VA, USA) were grown in DMEM (4.5 g glucose/L) +
5% fetal calf serum at 5% CO2 and 37°C. Flp-In T-REx 293 cells
with inducible overexpression of GPR120-enhanced yellow
fluorescent protein (eYFP) or GPR40-eYFP were grown in
DMEM (4.5 g glucose/L) + 10% fetal calf serum at 5% CO2 and
37°C.All cell linesweremycoplasma negative, andC26 andLLC
cells were also tested for mouse pathogens according to the
Federation of European LaboratoryAnimal ScienceAssociations
panel and were found to be negative.
Preparation of sCM from splenocytes
Spleens from splenectomized mice were used to make sCM.
Single-cell suspensions were made from spleens and red blood
cells were lysed by using red blood cell lysis buffer (155 mM
NH4Cl, 10 mM KHCO3, and 0.1 mM EDTA). Splenocytes were
sorted by magnetic bead sort to isolate F4/80+ macrophages
before 16:4(n-3) and 12-S-HHT incubation according to a pre-
viously described protocol (22). Magnetic-activated cell sorted
(MACS)-isolated splenocytes were incubated in serum-free me-
dium (DMEM, 4.5 g glucose/L) with 25 nM 16:4(n-3) or 20 nM
12-S-HHTfor1hat 5%CO2and37°C.After incubation, supernatant
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from the splenocytes was harvested, filtered through a 0.2-mm
filter, and stored at280°C until use. For preparation of sCMwith
AH-7614, splenocytes were preincubated for 10 min with 1 mM
AH-7614 before adding 16:4(n-3) for an additional 1 h. Spleno-
cytes that were incubated with 16:4(n-3) and GW1100 or
AACOCF3 were preincubated for 30 min with 10 mM of the
compounds before addition of 16:4(n-3). GW9508 (100 mM),
NCG21 (100 mM), TUG-891 (10 mM), and TUG-1197 (10 mM)
were incubated with splenocytes for 1 h before harvesting sCM
as described above.
FACS sorting and quantitative PCR analysis
of GPCRs
Single-cell suspensions were made from the spleen, and
red blood cells were lysed as described above. Next, spleno-
cytes were incubated with F4/80-FITC and CD11b-APC
(concentration 1 ml/1 3 107 cells/100 ml) or corresponding
isotype controls (FITC and APC; both from eBioscience) in
FACS buffer for 30 min on ice. F4/80+/CD11blow, F4/80+/
CD11bhigh, F4/802/CD11bhigh and F4/802/CD11b2 pop-
ulations were sorted by using a FACSAria III (BD Biosci-
ence, Brea, CA, USA). Gates for sorting were set according
to unstained and isotype control–stained samples. RNA
was extracted from FACS-sorted splenic populations by
using Trizol (Thermo Fisher Scientific, Waltham, MA,
USA). cDNA was synthesized by using Superscript II
(Thermo Fisher Scientific) according to manufacturer pro-
tocol using oligo dTs (Thermo Fisher Scientific). Mouse
primers used were as follows: for detection of GPR40, for-
ward: 59-GCTATTCCTGGGGTGTGTGT-39, reverse: 59-
CCCTGTGATGAGTCCTAACT-39; GPR41, forward: 59-CT-
GCTCCTGCTCCTCTTC-39, reverse: 59-CCAGGCGACTG-
TAGCAGTA-39; GPR43, forward: 59-GGCTTCTACAGC-AG
CATCTA-39, reverse: 59-AAGCACACCAGGAAATTA-
AG-39; GPR84, forward: 59-TCCAATTCTGTCTCCATCCT-
39, reverse: 59-CTGACTGGCTCAGATGAAA-39; and
GPR120, forward: 59-CCATCCCTCTAGTGCTCGTC-39, re-
verse: 59-TGCGGAAGAGTCGGTAGTCT-39. For quantita-
tive PCR analysis of human spleen, CD163+ and CD1632
splenocyteswere first isolated bymagnetic bead sort using the
same protocol as formouse spleen except for the Abs (22). Abs
used were as follows: mouse anti-human CD163-APC (con-
centration: 5 ml/1 3 107 cells/100 ml; eBioscience) and anti-
APC (concentration: 10 ml/1 3 107 cells/100 ml; Miltenyi
Biotec, Bergisch Gladbach, Germany). Next, RNA was also
isolated by using Trizol, and cDNAwas synthesized by using
Superscript II. Primers used for detection of human GPCRs
were: GPR40, forward: 59-GTGTCACCTGGGTCTGGTCT-
39, reverse: 59-GAGCAGGAGAGAGAGGC-TGA -39;
GPR41, forward: 59-TCTCAGCACCCTGAACTCCT -39, re-
verse: 59-TTCTGCTCCTTCAGCTCCAT-39; GPR43, for-
ward: 59-AAGGAGAAGGGATGCCAAGT-39, reverse:
59-GGGATACCAAGCTGGTGAAA -39; GPR84, forward:
59-TCAGCAGTGTTGGCATCTTC -39, reverse: 59-TAA-
CCTGCTGTCCAGCTCCT-39; GPR120, forward: 59-CTTC-
TTCTCCGACGTCAAGG-39, reverse: 59-AGAGGGATAG-
CGCTGATGAA-39; and GAPDH (glyceraldehyde 3-
phosphate dehydrogenase), forward: 59- CGACCACTT-
TGTCAAGCTCA-39, reverse: 59- AGGGGTCTACATGG-
CAACTG-39.
Immunohistochemistry
For immunohistochemistry experiments, murine tumors
were harvested 4 h after therapy. Healthy human spleen
tissuewas provided from the pathology biobank database of
the Netherlands Cancer Institute. Formaldehyde-fixed,
paraffin-embedded tissue sections were deparaffinated,
rehydrated, and incubated in endogenous peroxidase
blocking buffer that contained 5% H2O2. Antigen re-
trieval was performed by cooking slides in citrate buffer.
Tissue slides were blocked in 5% goat serum (Thermo
Fisher Scientific Life Sciences) in Tris-buffered saline/
Tween 20 (TBST) for gH2AX staining or in serum-free
protein block (Dako, Carpinteria, CA, USA) for GPR120
staining. Abs were used in the following dilutions: rabbit
anti-gH2AX (1:200) in 5% goat serum in TBST overnight at
4°C (Cell Signaling Technologies) and rabbit anti-GPR120
(1:1000) in Bright Diluent (Immunologic), also overnight
at 4°C. Poly-HRP goat anti-rabbit/rat/mouse (Immuno-
logic) was used as secondary Ab, followed by 3,39-
diaminobenzidine staining. Slides were counterstained
with hematoxylin. Each tumor slide was scanned by using
a Leica Aperio Scanscope (Leica, Wetzlar, Germany), and
a minimum of 10 images per tumor were analyzed. To
determine the percentage of positive cells, a grid with 54
intersection points was used. A second examiner whowas
blinded to the treatment groups also quantified gH2AX
staining.
Western blot
F4/80+ cells were isolated from murine spleens by using
magnetic bead sorting. Spleens were harvested from non–
tumor-bearing mice and a single-cell suspension was made.
After red blood cell lysis, splenocytes were resuspended in
FACS buffer [1% bovine serum albumin (BSA), 5 mM EDTA
in PBS, pH 7.4] and counted. Splenocytes were incubated
with rat anti-mouse F4/80 at a concentration of 3 ml/13 107
cells in 100 ml for 30 min on ice. After incubation, cells were
washed in FACS buffer and incubated with goat anti-rat
microbeads at a concentration of 5 ml/1 3 107 cells in 100 ml
for 15 min on ice (22). Again, cells were washed after Ab
incubation, resuspended in FACS buffer, and separated
according to manufacturer instructions using LS columns
(Miltenyi Biotec). F4/80+ splenocytes were incubated for
indicated times with 25 nM 16:4(n-3). After incubation, cells
were lysed and subjected to SDS-PAGE and Western blot-
ting. Membranes were blocked in either 5% BSA in TBST (for
phospho-cPLA2) or 5% nonfat milk in TBST (for actin) and
incubated overnight with Abs against phospho-cPLA2 (1:
1000 in 5% BSA in TBST) and actin (1:10,000 in 5% milk in
TBST). SecondaryAbs used for detectionwere diluted 1:7500
in 5% BSA in TBST (goat anti-rabbit HRP) or in 5% milk in
TBST (goat anti-mouse HRP).
cPLA2 and PLA1 activity measurements
F4/80+ splenocytes were lysed after incubating them for the
indicated times with 25 nM 16:4(n-3) [or 25 nM 16:4(n-3) and
a 10-min preincubation of 10 mM AH-7614], and cPLA2 or
PLA1 activity was measured by using EnzChek PLA2 or
EnzChek PLA1 assay kit, respectively (Thermo Fisher Sci-
entific), according to manufacturer protocol.
Ca2+ mobilization assay
GPR120 and GPR40 Flp-In T-REx 293 cells were plated at 50,000
cells/well in black 96-well plates with clear bottoms. Cells were
then treated with 100 ng/ml doxycycline to induce receptor ex-
pression and were maintained overnight at 37°C and 5% CO2
before use. Cells were labeled for 45 min with Fura2-AM fol-
lowed bywashing andmaintenance in HBSS. Fura-2 fluorescent
emissionat 510nmresulting from340or 380nmof excitationwas
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then monitored before and for 90 s after the addition of test
compoundusingaFlexstation II plate reader (MolecularDevices,
Sunnyvale, CA, USA). Ca2+ responses were taken as the peak
340/380 ratio measured after compound addition and normal-
ized to the maximal response obtained to either a-linolenic acid
(aLA) or 16:4(n-3) as indicated.
b-Arrestin2 recruitment assay
HEK293T cells were cotransfected by using polyethyleneimine
with FLAG-GPR120-eYFP and nanoluciferase (NLUC)-
b-arrestin2 plasmids or FLAG-GPR40-eYFP and NLUC-
b-arrestin2 plasmids in a ratio of 4:1. At 24 h post-transfection,
cellswere plated into poly-D-lysine–coated,white, 96-well tissue
culture plates and maintained for a further 24 h before experi-
ments. For experiments, cells were first washed and then in-
cubated at 37°C for 30 min in HBSS. NLUC NanoGlo substrate
(Promega,Madison,WI, USA)was addedwith a final dilution
of 1:800 before a further incubation for 10 min at 37°C. Test
compounds were then added at the specified concentration,
and cells incubated for a final 5 min before measuring lumi-
nescent emission at 530 and 465 nm using a ClarioStar plate
reader (BMGLabtech, Cary, NC, USA). The 530/465 emission
ratio was calculated and corrected for the ratio obtained in
cells that were transfected with only the NLUC-b-arrestin2
plasmid before being normalized to the maximal response
obtained to 16:4(n-3).
Patient samples
Blood samples were collected from 35 patients with cancer
before and 4 h after receiving chemotherapy at the Uni-
versityMedical Center Utrecht. The studywas approved by
the Institutional Ethical Review Board of the University
Medical Center Utrecht, and written informed consent was
obtained from all patients. Blood was collected in a cell
preparation tube. Peripheral blood mononuclear cells
and plasma were isolated. Plasma was stored immediately
at 280°C. Levels of LPC(24:1) were determined in the cit-
rate plasma samples of 19 patients who received platinum-
based chemotherapy and 16 patients who received non–
platinum-based chemotherapy.
16:4(n-3) measurements
16:4(n-3) measurements were performed as previously de-
scribed (21). In brief, a total lipids fraction was extracted from
conditioned medium derived from cisplatin-stimulated mu-
rine bonemarrowmesenchymal stem cells by amodified Bligh
and Dyer extraction performed according to Retra et al. (28).
Lipid extracts were analyzed by using single reaction moni-
toring on a triple-quadrupole mass spectrometer (Xevo,
Waters, St. Quentin, France) supported by ultra-performance
liquid chromatography (Waters).
LPC analysis of sCM samples and patient
plasma samples
Total lipids from sCM or plasma were extracted by using a
modified Bligh and Dyer extraction performed according to
Retra et al. (28). LPC analysiswas performed byusing amodified
methodofRetra et al. (28).Here, theHPLCcolumnwas replaceby
a fused core HALO C18 column (Biotech, Onsala, Sweden). To
increase sensitivity, LPCs were detected in multiple reaction
monitoring mode, in which a collection of 36 different LPC
masses (14:0 to 26:6 LPC) were monitored and confirmed by the
formation of a phosphocholine fragment of 184 m/z (collision
energy was 55 V). Furthermore, the fatty acid composition of
LPCs was confirmed by the presence of the corresponding fatty
acid fragment in a second mass spectrometry analysis. To
quantify LPC(24:1) levels in patient plasma, a standard curve
of LPC(24:1) was used.
LPC(24:1) production
1,2-Dinervonoyl-phosphatidylcholine [PC(24:1/24:1)] was
purchased from Avanti Polar Lipids (chloroform dissolved;
Alabaster, AL, USA) and converted in vitro into LPC(24:1) by
addition of sPLA2. Chloroform was evaporated under a
stream of nitrogen to yield 20 mmol of dried PC(24:1), after
which it was sonicated in 1 ml PLA2 buffer (10 mM TRIS-
HCl, 100 mM NaCl, 2 mM CaCl2, pH 7.4) that contained 1%
lipid-free BSA to form liposomes. Incubation with 2 U of
pancreas sPLA2 for 20 h at ambient temperature yielded an
80–90% conversion of PC(24:1/24:1) to LPC(24:1). The
conversion was monitored by mass spectrometry. Sub-
sequently, proteins (BSA and PLA2) were removed by a Bligh
and Dyer lipid extraction.
Statistical analysis
All data are presented as means6 SEM. Statistical significance
for all animal experiments in which tumor volumes were
assessed was determined by 1-way ANOVA with Tukey’s
correction for multiple testing. All other data were analyzed
by using 2-tailed Student’s t test. A value of P , 0.05 was
considered statistically significant. Levene’s test was used to
determine whether variance between groups was compara-
ble. Animals were excluded from analysis if $2 tumor mea-
surements were significant outliners compared with the rest
using the Grubbs outlier test (a = 0.05).
RESULTS
16:4(n-3) is an agonist for both GPR40
and GPR120
To assess whether 16:4(n-3) might activate GPR40 and/or
GPR120, we performed [Ca2+]i flux experiments using
an HEK293-based cell system that allowed inducible
expression of either GPR40 or GPR120. 16:4(n-3) pro-
duced a concentration-dependent elevation of [Ca2+]i in
cells that expressed either GPR40 or GPR120, whereas
this was absent from cells that were not induced to ex-
press these receptors (Fig. 1A, B), which demonstrated
that this fatty acid is an agonist of both GPR40 and
GPR120. The potency of 16:4(n-3) to produce [Ca2+]i
responses via each GPCR was somewhat greater than the
more widely studied 18:3(n-3) fatty acid, aLA, which was
used as a positive control. The effect of 16:4(n-3) in GPR40-
expressing cells was blocked by pretreatment with the
GPR40-specific antagonist, GW1100 (3), but not by the
GPR120-specific antagonist, AH-7614 (Fig. 1C) (26). By
contrast, in GPR120-expressing cells, AH-7614 but not
GW1100 prevented response to 16:4(n-3) (Fig. 1D). In ad-
dition, 16:4(n-3) also promoted recruitment of b-arrestin2
to both GPR40 and GPR120. This again was blocked at
each receptor only by the corresponding antagonist
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Figure 1. 16:4(n-3) induces elevation of [Ca2+]i and recruitment of b-arrestin2 in GPR40- and GPR120-expressing cells. A, B) 16:4(n-3) is
able to induce a [Ca2+]i response in GPR40- (A) and GPR120-expressing (B) Flp-In T-REx 293 cells. 16:4(n-3) activates both receptors
with a higher potency than aLA, which was used as a positive control; Flp-In T-REx 293 cells without doxycycline (dox; i.e., no GPR40/
120 expression) were used as negative controls. C) A GPR40-specific antagonist (GW1100, 10 mM) was able to block 16:4(n-3)-mediated
activation of GPR40, whereas a GPR120-specific antagonist (AH-7614, 10 mM) had no effect. D) AH-7614 was able to block 16:4(n-3)-
mediated activation of GPR120, whereas GW1100 had no effect. E, F) b-Arrestin2 is recruited to both GPR40 (E) and GPR120 (F)
receptors after stimulation with increasing concentrations of 16:4(n-3). Recruitment to GPR40 was blocked by addition of GW1100 but
not by AH-7614. Recruitment of b-arrestin2 to GPR120 upon stimulation with 16:4(n-3) was inhibited by AH-7614 but not GW1100.
Panels A and B show grouped results of 2 independent experiments with similar outcome, whereas panels C–F show grouped results of 3
independent experiments with similar outcome. BRET, bioluminescence resonance energy transfer. Data are presented as means6 SEM.
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(Fig. 1E, F). All compounds used in this study are listed in
Table 1 and their structures shown in Fig. 2. Taken to-
gether, 16:4(n-3) is a novel agonist of GPR40 and GPR120.
GPR40 and GPR120 are expressed on
splenic macrophages
To assess the relevance of these pharmacologic ex-
periments to resistance-inducing splenic macrophages
in vivo, we isolated splenic subpopulations on the ba-
sis of their expression of macrophage markers F4/80
and CD11b (Fig. 3A). Quantitative RT-PCR analysis
showed that GPR40 and GPR120 were expressed
exclusively within the spleen by F4/80+/CD11blow
splenocytes (Fig. 3B) that have previously been shown
to induce 16:4(n-3)-mediated chemoresistance (22).
The F4/80+/CD11blow population also expressed de-
tectable levels of both short-chain fatty acid receptors,
GPR43 and GPR41; however, these receptors respond
only to fatty acids with a chain length of ,7 carbons
(29) and were not considered further.
GPR40 and GPR120 agonists recapitulate
16:4(n-3)-mediated chemoresistance in vivo
We next assessed whether the synthetic dual GPR40
and GPR120 agonists, GW9508 and TUG-891, could
induce chemotherapy resistance in vivo. Isolated sple-
nocytes cultured in vitro were treated with fatty acid
16:4(n-3) or with either GW9508 or TUG-891. This sCM
was then injected into splenectomized tumor-bearing
mice, along with cisplatin. As observed previously (21,
TABLE 1. GPR40 and GPR120 agonists and antagonists
Compound
pEC50
GPR40
pEC50
GPR120 Formula Study
Agonist
TUG-891 4.2 7.4 C23H21FO3 Shimpukade et al. (25), Hudson et al. (30)
GW9508 6.6–7.3 5.5 C22H21NO3 Briscoe et al. (3), Hudson et al. (30)
NCG21 4.7 5.9 C23H23N2O3 Sun et al. (24), Hudson et al. (30)
TUG-1197 ,4.0 6.9 C18H13N2O3 Azevedo et al. (27)
Antagonist
GW1100 6.0 ,5.0 C27H25FN4O4S Briscoe et al. (3)
AH-7614 ,4.6 7.1 C20H17NO3S Sparks et al. (26)
Figure 2. Chemical structures of GPR40 and/or GPR120 agonists and antagonists—all compounds used in this study.
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22), the reduction in tumor volume that was produced
14 d after cisplatin treatment was abolished by coin-
jection of 16:4(n-3)–sCM. This effect was fully re-
capitulated by conditionedmedium thatwas generated
after treatment of splenocytes with either GW9508 or
TUG-891, which implied that activation of GPR120
and/or GPR40 is either directly involved in, or can
mimic, 16:4(n-3)-mediated chemoresistance in vivo (Fig.
3C). AlthoughGW9508 is a GPR40-selective agonist (3),
it is well established to also display agonism at
Figure 3. GPR40 and GPR120 are expressed by splenic macrophages, and dual GPR40 and GPR120 agonists recapitulate 16:4(n-
3)-mediated chemoresistance in vivo. A) FACS analysis of BALB/c mouse spleen stained for F4/80 and CD11b. B) Indicated
populations were sorted and relative expression of the free fatty acid receptors GPR40, GPR41, GPR43, GPR84, and GPR120 on
these populations was determined by quantitative PCR. mRNA expression levels were normalized to GAPDH (glyceraldehyde 3-
phosphate dehydrogenase) control. C) sCM derived from splenocytes that were incubated with the dual GPR40 and GPR120
agonists TUG-891 or GW9508 induce chemoresistance in vivo to an extent similar to sCM derived from splenic macrophages that
were incubated with 16:4(n-3). The illustration below the data sets illustrates the approach used to generate sCM and its injection
into tumor-bearing mice. D) Coadministration of cisplatin (cis) and sCM from splenocytes that were cultured in the presence of
NCG21 (another GPR40/GPR120 agonist) induces chemotherapy resistance in splenectomized, tumor-bearing BALB/c mice.
Panels B and D show grouped results of 2 independent experiments with similar outcomes (B: n = 4 per group; D: n = 8 per
group). Panel C shows grouped results of 3 independent experiments with similar outcomes (n = 12 per group). Data are
presented as means 6 SEM. Statistical significance was determined by 1-way ANOVA (C, D) or 2-tailed Student’s t test (B); all
compared with cisplatin alone unless indicated otherwise. *P , 0.05; **P , 0.01.
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GPR120 and, indeed, has often been used as an acti-
vator of GPR120 in cell types in which GPR40 is not
expressed [e.g., Oh et al. (9)]. Similarly, although
TUG-891 is a GPR120-selective agonist, it also dis-
plays significant potency at GPR40, particularly at
the mouse ortholog of this receptor (30). In addition,
sCM that is derived from splenocytes incubated with
NCG21, another GPR40 and GPR120 dual agonist
(31), also induced chemoresistance (Fig. 3D).
Antagonism of GPR120 prevents
16:4(n-3)-mediated chemoresistance in vivo
Because F4/80+/CD11blow splenocytes express both
GPR40 and GPR120, and GW9508, TUG-891, and
NCG21 are not selective enough to differentiate be-
tween the 2 receptors in this system, we used addi-
tional pharmacologic tool compounds to determine
which receptor(s) were relevant for 16:4(n-3)-mediated
chemoresistance. First, we tested the ability of a
GPR120-specific antagonist—AH-7614—and a GPR40-
specific antagonist—GW1100—to block the chemo-
resistance effect of 16:4(n-3) in vivo. We found that
preincubation of splenic macrophages with AH-7614
(GPR120 antagonist) completely prevented 16:4(n-3)-
mediated chemoresistance, whereas this was not
achievedwith the GPR40-specific antagonist GW1100
(Fig. 4A). These results implied that 16:4(n-3) pro-
duces chemoresistance by activating GPR120 and not
GPR40. To further support this conclusion, we tested the
ability of a recently described GPR120-specific agonist—
TUG-1197—that has no activity at GPR40 (27) to induce
chemoresistance. As anticipated, coadministration of cis-
platin and conditioned medium derived from splenocytes
that were incubated with TUG-1197 induced chemo-
resistance to an extent similar to sCM from 16:4(n-3)-
exposed splenocytes (Fig. 4A).
PIFAs are able to alter the DNA damage re-
sponse in tumor cells, which leads to chemo-
resistance. Compared with cisplatin monotherapy,
coadministration of 16:4(n-3)–sCM with cisplatin led
to a decrease in gH2AX levels—a measure of double
strand DNA breaks—4 h after treatment. By contrast,
in mice that were treated with conditioned medium
from splenocytes that were cotreated with 16:4(n-3)
and AH-7614, this effect was absent (Fig. 4B). An-
tagonism of GPR120 thus blocks chemoresistance
both in tumor volumetric experiments and at the level
of gH2AX in tumors, which indicates that GPR120 is
the functional receptor transducing 16:4(n-3)-
mediated chemoresistance.
sCM derived from GPR1202/2 mice fails to
induce 16:4(n-3)-mediated chemoresistance
Pharmacologic characterization suggested that the effect of
16:4(n-3) is produced via activation of splenocyte-expressed
GPR120; therefore, we hypothesized that the che-
moresistance effect of 16:4(n-3) would be absent if
splenocytes from GPR120-deficient mice were used.
Figure 4. 16:4(n-3)-induced chemotherapy resistance is mediated via GPR120 in vivo. Treatment of C26 tumor-bearing BALB/c
mice with cisplatin (cis) and sCM derived from splenocytes that were stimulated with GPR120-specific agonist TUG-1197 induces
chemoresistance, which indicates a central role for GPR120 in 16:4(n-3)-mediated resistance. A) GPR120-specific antagonist AH-
7614 was able to completely block 16:4(n-3)-mediated resistance, whereas GPR40-specific antagonist GW1100 was ineffective.
Tumors of mice that were treated with cisplatin and sCM + 16:4(n-3) showed a decrease in gH2AX levels 4 h after treatment
compared with animals treated with cisplatin alone. B) Mice that were treated with cisplatin and sCM + 16:4(n-3) + AH-7614 had
gH2AX levels similar to mcie treated with cisplatin alone. Scale bars, 50 mm. All experiments in this figure were conducted in C26
tumor-bearing BALB/c mice. All graphs show grouped results of 2 independent experiments with similar outcomes (n = 8 per
group). Data are presented as mean6 SEM. Statistical significance was determined by 1-way ANOVA (A) or 2-tailed Student’s t test
(B); all compared with cisplatin alone unless indicated otherwise. *P , 0.05; **P , 0.01.
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As anticipated, we found that sCM obtained from
splenocytes that were isolated from GPR1202/2mice
and incubated with 16:4(n-3) did not induce chemo-
resistance when introduced into wild-type, tumor-
bearing mice, whereas sCM from wild-type mice on
the same genetic background did (Fig. 5A, B). This
was true whether chemoresistance was assessed via
tumor volumetric measurements or gH2AX immu-
nohistochemical analysis (Fig. 5C).
16:4(n-3) is not the only PIFA (21). The hydroxyl fatty
acid, 12-S-hydroxy-5,8,10-heptadecatrienoic acid (12-S-
HHT), is known to induce chemoresistance by activating
leukotriene B4 receptor signaling in splenic macrophages.
As anticipated, the capacity of 12-S-HHT to cause
chemoresistance was not hampered by the genetic loss of
GPR120 (Fig. 5B, C).
Activation of GPR120 by 16:4(n-3) leads to
enhanced cPLA2 activity
Having established a role for GPR120 that is expressed by
F4/80+/CD11blow splenocytes in initiation of resistance to
cisplatin,wenext set out todefine themechanistic basis for
this effect. It is known that PIFA-activated splenic mac-
rophages produce 6 unsaturated LPCs that have the po-
tential to act as effector molecules of resistance to cisplatin
(22). Production of LPC from PC may be mediated by
various enzymes, which leads to the generation of
Figure 5. sCM derived from GPR1202/2 mice is unable to induce 16:4(n-3)-mediated chemoresistance. A) sCM from wild-
type C57BL/6 mice that were incubated with either 16:4(n-3) or 12-S-HHT was able to induce resistance against cisplatin
(cis) in wild-type C57BL/6 splenectomized, tumor-bearing mice. B) sCM of GPR1202/2 mice that were incubated with
16:4(n-3) was unable to induce chemoresistance when coinjected with cisplatin in wild-type LLC tumor-bearing C57BL/6
mice, whereas sCM from GPR1202/2 mice that were incubated with 12-S-HHT retained the ability to induce resistance. C)
gH2AX levels in tumors treated with cisplatin and sCM GPR1202/2 + 16:4(n-3) were similar to those of tumors treated with
cisplatin monotherapy, whereas tumors that were treated with cisplatin and sCM wild-type + 16:4(n-3) or sCM wild-type + 12-S-
HHT or sCM GPR1202/2 + 12-S-HHT showed significantly lower gH2AX levels. Scale bars, 50 mm. All graphs show grouped
results of 2 independent experiments with similar outcomes (n = 8 per group). Data are presented as means 6 SEM. Statistical
significance was determined by 1-way ANOVA (A, B) or 2-tailed Student’s t test (C); all compared with cisplatin alone unless
indicated otherwise. *P , 0.05; **P , 0.01; ***P , 0.001.
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Figure 6. 16:4(n-3) stimulation increases cPLA2 activity in splenic macrophages. A) Schematic overview of hydrolysis sites of PC to
yield metabolites, such as LPC. Splenic macrophages were harvested from murine BALB/c spleens by magnetic bead sorting
using F4/80 Abs. Macrophages were incubated with either vehicle or 16:4(n-3) (25 nM) for indicated times. B, C) Fluorescent-
based analysis of PLA1 and cPLA2 enzymatic activity revealed a decrease in PLA1 activity (B) and a significant time-dependent
increase in cPLA2 activity (C) upon stimulation with 16:4(n-3). Preincubation of splenic macrophages with the GPR120-specific
antagonist AH-7614 did not affect 16:4(n-3)-mediated changes in PLA1 activity but was able to prevent the 16:4(n-3)-induced
increase in cPLA2 activity. D) In addition, splenic macrophage cell lysates were analyzed by Western blot for phospho-cPLA2.
Actin was used as a loading control. E) Treatment of tumor-bearing BALB/c mice with cisplatin (cis) and sCM derived from
(continued on next page)
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structurally different LPCs. PLA1 can hydrolyze PC at the
sn-1 position and cPLA2 can hydrolyze PC at the sn-2
position,whereasPLBcancleavePCatbothpositions (Fig.
6A). To investigate which of these enzymes was involved
in16:4(n-3)-mediatedLPCproduction,weexaminedPLA1
and cPLA2 activity in splenic macrophages. We found no
up-regulation of PLA1 activity in splenic macrophages
upon treatment with 16:4(n-3) (Fig. 6B). Moreover, al-
though a statistically significant decrease in PLA1 activity
was detected after sustained exposure to 16:4(n-3), this
did not reflect activation of GPR120 because the effect
was not prevented by coincubation with the GPR120-
specific antagonist, AH-7614 (Fig. 6B). We noted a
significant increase in cPLA2 activity in the splenic
macrophage population after exposure to 16:4(n-3) via
both immunoblotting to detect active, phosphorylated
cPLA2 (Fig. 6C) and by directly measuring the enzy-
matic activity of cPLA2 (Fig. 6D). This effect was
blocked by pretreatment of splenocytes with GPR120
antagonist AH-7614 (Fig. 6C,D). To link cPLA2 activity
in splenocytes to the chemoresistance effect of 16:4(n-3),
we injected sCM generated from splenocytes that were
incubated with 16:4(n-3) and the cPLA2 inhibitor,
AACOCF3, into tumor-bearing mice and observed that
the chemoresistance effect of 16:4(n-3) was abolished by
the cPLA2 inhibitor (Fig. 6E).
GPR120 mediates 16:4(n-3) chemoresistance
via production of LPC(24:1)
PIFA-activated splenic macrophages that induce che-
moresistance produce 6 chemically distinct, unsaturated
LPCs. By using a lipidomics approach, we identified
which of these LPCs was released specifically upon 16:4
(n-3) stimulation of splenocytes fromwild-typemice and
whether this was altered in splenocytes that were iso-
lated from GPR1202/2 animals. When measuring LPC
levels in sCM derived from wild-type splenocytes that
were incubatedwith 16:4(n-3),we founda significant up-
regulationof 3 these6LPCs,namelyLPC(20:5), LPC(22:3),
and LPC(24:1) (Fig. 7A). By contrast, when equivalently
conditionedmedium from splenocytes that were isolated
from GPR1202/2 animals was analyzed, only LPC(20:5)
and LPC(22:3) were up-regulated, which suggested a
specific role for GPR120 in the release of LPC(24:1) (Fig.
7A). Of importance, the cPLA2 inhibitor, AACOCF3, also
greatly reduced LPC(24:1) production from splenocytes
in response to16:4(n-3) treatment (Fig. 7A). To testdirectly
if LPC(24:1) was the resistance-inducing molecule se-
creted by 16:4(n-3)-activated splenic macrophages, we
coinjected LPC(24:1) with cisplatin into splenectomized,
tumor-bearing mice and found that this treatment did
indeed induce chemoresistance, whereas the closely
related LPC(24:0) did not (Fig. 7B). In line with these
findings, immunohistochemical analysis of tumors
that were treated with cisplatin and LPC(24:1) showed
decreased levels of gH2AX+ cells compared with cis-
platinmonotherapy or cisplatin combinedwith LPC(24:0)
(Fig. 7C).
GPR120-induced chemoresistance by 16:4(n-3)
is context dependent
We next assessed whether our findings could be gener-
alized to other macrophage-like populations. RAW264.7
cells are a macrophage-like cell line known to express
GPR120. In such cells, activation of GPR120 is able to
suppress production of inflammatory mediators, in-
cluding TNF-a, that are induced by treatmentwith such
agents as LPS (30). In addition, it has been shown that
activation of cPLA2 via GPR120 in RAW264.7 cells in-
duces an anti-inflammatory response (10); however,
sCMderived fromRAW264.7 cells thatwere stimulated
with 16:4(n-3) did not induce chemoresistance, nor did
we find an up-regulation of phospho-cPLA2 in, or
production of, LPC(24:1) by these cells, which indicated
that GPR120-induced production of 16:4(n-3)-mediated
chemoresistance is context dependent (Supplemental
Fig. 2).
Human splenic macrophages express GPR120,
and LPC(24:1) is detected in patients who
received platinum-based chemotherapy
To assess the potential clinical applicability of our che-
moresistance model, we determined expression levels
of GPR40, GPR41, GPR43, GPR84, andGPR120 in human
CD163+ and CD1632 splenocytes. CD163 is a marker
for splenic red pulp macrophages in humans and is
the closest analog to murine F4/80. Human CD163+
splenocytes showed increased expression of GPR40 and
GPR120 compared with CD1632 splenocytes, which
correlated with findings in mice; however, some GPR120
was also detected in CD1632 splenocytes, which was
indicative of a broader expression pattern in humans
compared with mice (Fig. 8A). In support of this, im-
munohistochemistry showed stronger GPR120 stain-
ing in red pulp of the spleen (Fig. 8B). The splenic red
pulp harbors tissue resident macrophages that are
known for their role in iron homeostasis and has
previously been identified as the location for murine
F4/80+/CD11blow macrophages that are known to
induce chemoresistance (22, 32). Next, we measured
LPC(24:1) levels in patients who were treated with
either platinum-containing chemotherapeutics or
non–platinum-containing chemotherapeutics before
splenocytes that were incubated with 16:4(n-3) and AACOCF3 did not induce chemoresistance, whereas cotreatment with
cisplatin and sCM+ 16:4(n-3) did. Panel B shows grouped results of 2 independent experiments with similar outcomes. Panels C
and D show results of 4 independent experiments. Panel E shows grouped results of 2 independent experiments with similar
outcomes (n = 8 per group). Data are presented as means6 SEM. Statistical significance was determined by 2-tailed Student’s t test
(B, C) or 1-way ANOVA (E); all compared with vehicle control (B, C) or with cisplatin alone (E) unless indicated otherwise. *P,
0.05; **P , 0.01.
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and 4 h after administration of chemotherapy. We
found increased plasma LPC(24:1) levels 4 h after
treatment in patients who received platinum-based
chemotherapy compared with patients who were
treated with non–platinum-based chemotherapeutics
(Fig. 8C). Additional studies will reveal if LPC(24:1)
can be used as an early marker for chemotherapy re-
sistance in platinum-treated patients.
DISCUSSION
Here, we identified the PIFA, 16:4(n-3), as a novel and
endogenouslyproduced agonist ofGPR120 anddescribe a
function forGPR120 in inducing chemotherapy resistance.
16:4(n-3)–GPR120 signaling in splenic macrophages en-
hances production and release of LPC(24:1), thus leading
to chemotherapy resistance in vivo (Fig. 8D). GPR120 is a
Figure 7. LPC(24:1) secretion is specifically up-regulated upon 16:4(n-3) stimulation of splenic macrophages. A) LPC analysis of sCM
from wild-type mice that were incubated with 16:4(n-3) revealed 3 significantly up-regulated unsaturated LPCs compared with vehicle
control–incubated splenic macrophages. LPC(24:1) up-regulation in wild-type sCM was lost in GPR1202/2 sCM. In addition, LPC(24:1)
was also lost when splenocytes were incubated with 16:4(n-3) in the presence of the PLA2 inhibitor AACOCF3. B) Coadministration
of cisplatin (cis) and 10 nmol LPC(24:1) was sufficient to induce chemotherapy resistance, whereas coadministration of cisplatin and
10 nmol of LPC(24:0) could not. C) Tumors of mice that were treated with cisplatin and LPC(24:1) had levels of gH2AX similar to
control mice, whereas mice that were treated with cisplatin alone or cisplatin and LPC(24:0) showed increased levels of gH2AX
compared with control mice. Analysis of gH2AX was performed 4 h post-treatment. Scale bars, 50 mm. Experiments in Panels B and C
were conducted in C26 tumor-bearing BALB/c mice. All graphs show combined results of 2 independent experiments with similar
outcomes (A: n = 4 per group; B: n = 8 per group; C: n = 8 per group). AUC, area under the curve; ns, not significant. Data are
presented as means 6 SEM. Statistical significance was determined by 1-way ANOVA (B, C) or 2-tailed Student’s t test (A, D); all
compared to cisplatin alone unless indicated otherwise. *P , 0.05; **P , 0.01.
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receptor for long-chain fatty acids (2) and, in certain
studies, activation byv-3 fatty acids of GPR120 has been
highlighted (5, 9, 10). The relatively high expression of
GPR120 in adipose tissue, macrophages, and intestine
has resulted, to date, in a focus on its contribution to
insulin signaling, obesity, and anti-inflammatory re-
sponses and, on the basis of these, the potential for
GPR120 agonists to regulate glucose homeostasis and act
as potential medicines to treat type II diabetes (7). Vari-
ous studies, however, have also suggested a role for
GPR120 in tumor progression. Overexpression of GPR120
in colorectal carcinomas has been associated with an-
giogenic switching and cell motility (33). Similarly, in
pancreatic cancer cell lines, down-regulation of GPR120
prevented cellmigration (34). In contrast, in prostate cancer,
GPR120 signaling seems to have an antitumor effect (35).
Numerousdistinct fatty acids can activateGPR120, and
their downstream effects may differ between cell and tis-
sue types, generating the reported complexity of fatty acid
signaling in cancerbiology.Here,we identified16:4(n-3) as
a novel agonist of GPR120 and showed that activation of
GPR120 by 16:4(n-3) in splenic macrophages leads to
Figure 8. Human splenic macrophages express GPR120, and LPC(24:1) is increased in blood plasma of patients who were treated with
platinum-containing chemotherapeutics. A) Relative expression of GPR40, GPR41, GPR43, GPR84, and GPR120 in human CD163+ and
CD1632 splenocytes was determined by quantitative PCR. GPR40 and GPR120 are expressed by human splenocytes. B) Immuno-
histochemical staining of GPR120 on human splenic tissue reveals GPR120+ cells in red pulp of the spleen. Scale bars, 100 mm (top),
20 mm (bottom). C) LPC(24:1) measurements in patient plasma showed increased LPC(24:1) levels in patients after treatment with
platinum-based chemotherapeutics but not in patients who were treated with non–platinum-based chemotherapeutics (n = 19 platinum-
based chemotherapy; n = 16 non–platinum-based chemotherapy). D) Overview illustration of the identified 16:4(n-3)–GPR120 signaling
axis in splenic macrophages. Panel A shows representative results of 2 independent experiments. GAPDH, glyceraldehyde 3-phosphate
dehydrogenase. Data are presented as means 6 SEM. Statistical significance was determined by 2-tailed Student’s t test.
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increased cPLA2 activity and the associated increased
secretion of LPC(24:1), which subsequently results in
resistance to chemotherapy in vivo. Of interest, mea-
surements of LPC(24:1) levels in the plasma of patients
who received platinum-based chemotherapy showed
an increase 4 h after administration of chemotherapy
compared with baseline levels, which is suggestive
of a human correlate with mouse-based studies.
It is important to note, however, that the capacity of
GPR120 to initiate a signaling cascade that results in se-
cretion of LPC(24:1) is context dependent. Although
macrophage-like model cell systems, such as RAW264.7
cells, are frequently used to explore aspects of macro-
phage biology and have been used to explore potential
pathways linked to anti-inflammatory signals induced
by GPR120 (10, 30), we were unable to observe pro-
duction of LPC(24:1) upon addition of 16:4(n-3) to such
cells. This demonstrates that such transformed cell lines
may not always accurately mimic the behavior and
function of primary cells.
That such transformed cell lines do not accurately
mimic the behaviors and functions of native cells is per-
haps intrinsically obvious, but these observations provide
a useful cautionary note for potential overinterpretation
of results that rely exclusively on such models.
Little is known about the function of LPCs, and, in
particular, LPC(24:1), in tumor progression and anti-
cancer drug resistance. Schneider et al. (36) showed that
LPC and lysophosphatidic acid (LPA) induce migration
andmetastasis of rhabdomyosarcoma in vitroand in vivo.
In addition, LPC and LPA levels increased when mice
were treated with either vincristine or radiotherapy,
postulating the hypothesis that the treatment-induced
increase in LPC and LPA would facilitate metastasis. In
contrast, Raynor et al. (37) showed that LPCs are rapidly
metabolized by cancer cells and that they can prevent
metastasis.
Because chemotherapy resistanceposes one of themain
problems in effective treatment of patients with cancer,
insights into these mechanisms are of importance to
identify new targets that could enhance the efficacy of
chemotherapy. Our findings suggest that intricate lipid-
signaling betweennoncancerous host cells and tumor cells
can affect chemotherapeutic drug sensitivity. Identifica-
tion of GPR120 as a key receptor in this process shows
potential for the use of GPR120 antagonists to enhance
chemotherapeutic efficacy.
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Supplemental figure 1: Bone marrow derived mesenchymal stem cells (BM-MSCs) 
produce 16:4(n-3) in response to cisplatin stimulation. Cultured MSCs were 
stimulated with vehicle, 1 uM cisplatin or 10 uM cisplatin for 4 hours. After 4 hours the 
medium was replaced by serum-free medium and harvested 24 hours later. This 
conditioned medium was analyzed by mass spectrometry for the presence of 16:4(n-3). 
Data shows combined data of two individual experiments with similar outcome. Data are 
expressed as mean ± SD. 
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Supplemental figure 2: RAW264.7 cells do not induce chemotherapy resistance in 
response to 16:4(n-3). CM prepared from RAW264.7 cells stimulated with 16:4(n-3) 
does not induce chemoresistance in BALB/c mice (panel a). No increase in phospho-
cPLA2 was seen by western blot analysis of RAW264.7 cells stimulated with 16:4(n-3) 
(25 nM) for indicated time points (panel b). LPC measurements in the CM from 
RAW264.7 cells incubated with either vehicle control or 16:4(n-3) showed overall low 
LPC levels and no significant changes between control and 16:4(n-3) stimulation (panel 
c). Graphs show results of two independent experiments (panel a n=8 per group, panel c 2 
replicates per treatment). Data are represented as mean ± SEM. Statistical significance 
was determined by two-tailed Students T-test (panel c) or one-way ANOVA (panel a). 
Panel a: all compared to cisplatin alone  * P<0.05 ** P<0.01. 
 
